Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by askretkaon Nov 14, 2023 10:05pm
296 Views
Post# 35735961

Target lowered to 5$ from 15$ at HC Wainwright

Target lowered to 5$ from 15$ at HC Wainwright Oncolytics price target lowered to $5 from $15 at H.C. Wainwright

H.C. Wainwright lowered the firm's price target on Oncolytics to $5 from $15 and keeps a Buy rating on the shares. The analyst says pelareorep demonstrated encouraging efficacy in anal cancer, while the company's clinical development path in pancreatic cancer shifts. The target drop reflects an increase in estimated expenses related to pela's clinical development and a potential launch in 2027, the analyst tells investors in a research note.

Got this summary from Thefly.com 
You can get more info by clicking on the link if you create a free account and sign in.

I find it quite useful at times for getting info on my investments. Cheers!!!!!!!!!!!!!!!!!!!!!





 
<< Previous
Bullboard Posts
Next >>